Publications

Journal Article
Review Research Support, Non-U.S. Gov't
Ppublish 155 citations
Electronic publication date
October 16, 2024

View on Pubmed.gov 38937626 | View on doi.org 10.1038/s41569-...

Autoimmune diseases and atherosclerotic cardiovascular disease.

Search for publications in this journal Nat Rev Cardiol - 21(11):780-807

Abstract

Autoimmune diseases are associated with a dramatically increased risk of atherosclerotic cardiovascular disease and its clinical manifestations. The increased risk is consistent with the notion that atherogenesis is modulated by both protective and disease-promoting immune mechanisms. Notably, traditional cardiovascular risk factors such as dyslipidaemia and hypertension alone do not explain the increased risk of cardiovascular disease associated with autoimmune diseases. Several mechanisms have been implicated in mediating the autoimmunity-associated cardiovascular risk, either directly or by modulating the effect of other risk factors in a complex interplay. Aberrant leukocyte function and pro-inflammatory cytokines are central to both disease entities, resulting in vascular dysfunction, impaired resolution of inflammation and promotion of chronic inflammation. Similarly, loss of tolerance to self-antigens and the generation of autoantibodies are key features of autoimmunity but are also implicated in the maladaptive inflammatory response during atherosclerotic cardiovascular disease. Therefore, immunomodulatory therapies are potential efficacious interventions to directly reduce the risk of cardiovascular disease, and biomarkers of autoimmune disease activity could be relevant tools to stratify patients with autoimmunity according to their cardiovascular risk. In this Review, we discuss the pathophysiological aspects of the increased cardiovascular risk associated with autoimmunity and highlight the many open questions that need to be answered to develop novel therapies that specifically address this unmet clinical need.

References

Ridker, P. M. et al. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials. Lancet 401, 1293–1301 (2023).

Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119–1131 (2017).

Fiolet, A. T. L. et al. Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials. Eur. Heart J. 42, 2765–2775 (2021).

Libby, P. The changing landscape of atherosclerosis. Nature 592, 524–533 (2021).

Cited by 155 citations (total)

Journal Article

Responsive probes for in vivo magnetic resonance imaging of nitric oxide.

Electronic publication date January 1, 2025

Search for publications in this journal Nat Mater

Chang Lu [...] Guosheng Song et al.

Nitric oxide (NO), a pivotal signalling molecule, plays multifaceted roles in physiological and pathological processes, including cardiovascular and immune functions,...

Clinical Trial, Phase III Journal Article Multicenter Study Randomized Controlled Trial

Intensive Lowering of LDL Cholesterol Levels With Evolocumab in Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER Trial.

Electronic publication date May 19, 2025

Search for publications in this journal Circulation

Andre Zimerman [...] Robert P Giugliano et al.

BACKGROUND

Patients with an autoimmune or inflammatory disease (AIID) are at increased cardiovascular risk and may benefit more from statin therapy....

Conflict of interest statement

No conflict of interest statement provided.

MeSH

Specialties

Copyright

© 2024. Springer Nature Limited.